BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 18370231)

  • 1. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.
    Lee NH
    Anticancer Agents Med Chem; 2010 Oct; 10(8):583-92. PubMed ID: 21194402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
    Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
    Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.
    Iyer L
    Mol Diagn; 1999 Dec; 4(4):327-33. PubMed ID: 10671643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
    Bertholee D; Maring JG; van Kuilenburg AB
    Clin Pharmacokinet; 2017 Apr; 56(4):317-337. PubMed ID: 27641154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics and individualized drug therapy.
    Eichelbaum M; Ingelman-Sundberg M; Evans WE
    Annu Rev Med; 2006; 57():119-37. PubMed ID: 16409140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
    Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
    Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
    Cascorbi I; Haenisch S
    Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.
    Yiannakopoulou ECh
    Pharmacogenomics J; 2013 Apr; 13(2):105-9. PubMed ID: 23044602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
    Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
    Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics and cancer chemotherapy.
    Iyer L; Ratain MJ
    Eur J Cancer; 1998 Sep; 34(10):1493-9. PubMed ID: 9893619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
    Quaranta S; Thomas F
    Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer pharmacogenomics: international trends.
    Yamayoshi Y; Iida E; Tanigawara Y
    Int J Clin Oncol; 2005 Feb; 10(1):5-13. PubMed ID: 15729594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
    Deeken JF; Figg WD; Bates SE; Sparreboom A
    Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics in cancer treatment.
    Nagasubramanian R; Innocenti F; Ratain MJ
    Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy.
    Evans WE
    Ther Drug Monit; 2004 Apr; 26(2):186-91. PubMed ID: 15228163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.